Board of Directors

Paul Buron

Paul Buron

Interim Chair, Former Executive Vice President, Government Mandate and Programs Management, Investissement Québec

Paul Buron has more than 30 years experience in financial management, risk management and business strategies, including as the Executive Vice-President, Government Mandates and Programs Management at Investissement Québec from 2017 to 2019, where he coordinated the full range of mandates, financial programs and tax measures administered by the organization on behalf of the Government of Québec through the Economic Development Fund (EDF).

From 2006 to 2017, Paul served as Executive Vice President and Chief Financial Officer of the Business Development Bank of Canada (BDC). Until 2016, he was also in charge of risk management for BDC. In 2011-2012, he held the post of Interim Executive Vice President, Financing and Consulting in addition to his other responsibilities.

Before joining the BDC team, Paul was Senior Vice President and Chief Financial Officer of TVA Group from 2000 to 2006. In that capacity, he was in charge of television operations and regional stations, IT services, investor relations and human resources.

He is a member of the boards of directors of Oxfam-Québec, and the Association of Québec Women in Finance mentoring program.

He holds a Bachelor of Business Administration from HEC Montréal, and was a member of the Ordre des comptables professionnels agréés du Québec (CPA) for more than 30 years.

Meena Ballantyne

Meena Ballantyne

Former Deputy Minister, Status of Women Canada

Meena Ballantyne has had a successful career in the federal Public Service of Canada where she held numerous senior positions, including Assistant Deputy Minister and Deputy Minister, Status of Women Canada. As the Assistant Deputy Minister of Health Products and Food Branch at Health Canada, she led the regulatory branch dealing with prescription drugs, biologics, medical devices and natural health products. She also served as Assistant Secretary for Social Development at the Privy Council of Canada where she provided advice to the Prime Minister and Clerk of the Privy Council on issues relating to health, immigration and criminal justice reforms. Meena has served on a number of boards, and holds a Director designation in corporate governance from the Institute of Corporate Directors.

Helen Burt

Helen Burt

Associate Vice-President, Research & Innovation, UBC

A founding scientist of adMare’s predecessor, The Centre for Drug Research and Development (CDRD), Dr. Helen Burt has had an esteemed career as Professor of Drug Delivery in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC),  where she also served as Associate Vice President, Research & International.

Her major research efforts have been supported by grants from CIHR and NSERC, and involve the development of polymer-based drug delivery systems for controlled and localized drug delivery. She has published more than 140 peer-reviewed papers and holds eight patents.

Helen has been the recipient of several teaching prizes and research awards, including the UBC Killam Teaching Prize and Killam Faculty Research Prize, NSERC Synergy Award for Innovation, CSPS Award of Leadership in Canadian Pharmaceutical Sciences,  the YWCA Woman of Distinction Award for Science, Research and Technology, and the LifeSciences British Columbia Lifetime Achievement Award.

Helen is  a member of the Canadian Academy of Health Sciences, and served on the Board of Directors of the Provincial Health Services Authority.

She obtained her B. Pharm. (Hons) from the University of Bath and her PhD in Pharmaceutics from UBC.

Theresa Firestone

Theresa Firestone

Director, Orion Biotechnology

Theresa Firestone is a global healthcare executive with expertise driving growth, developing strategy and overseeing operations in healthcare, including digital health and pharmaceuticals. She is a results-driven leader of high-performing teams known for developing talent and managing change in complex, cross-cultural matrix environments.

Theresa’s recent experience includes digital healthcare, health clinics, home healthcare retail, beauty clinics, medical Cannabis, long-term care, specialty health, health and wellness, business development, pharmacy point-of-care testing and services. She has been a Board Member of Orion Biotechnology since Oct. 2018. Prior to that, Theresa served as the Senior Vice President Health and Wellness and Senior Vice President, Healthcare and Business with Shoppers Drug Mart in Toronto.

Nancy Harrison

Nancy Harrison

Venture Partner, Amplitude Venture Capital

Nancy Harrison is former co-founder and the past President of MSI Methylation Sciences, a private venture-backed development company with a novel treatment of depression in Phase II development. She is a former Partner and Senior Vice President of Ventures West Management Inc.

During her tenure with Ventures West, the life sciences portfolio grew from 0% of the overall investment portfolio to approximately 30% of investments. The firm grew from about $90 million to about $750 million under management in eight historical funds. Nancy participated in over 30 investments over her time at the firm, and specialized in helping Canadian life sciences companies raise Series B rounds through accessing US venture capital funds. Some of these investments include companies such as Angiotech Pharmaceuticals, Inc., AnorMed, Inc, Caprion Pharmaceuticals Inc., Celator Technologies Inc., Alder Biopharmaceuticals, Xenon Pharmaceuticals Inc., Salmedix Inc., Sembiosys Genetics Inc., and many other biotechnology firms while with Ventures West.

Nancy has served as Chair of Life Sciences BC, and Board member of NRC IRAP, Presentation House as well as other not-for-profit organizations. She has won The Canadian Caldwell Partners 40 Under 40 Award for outstanding young business professionals and Business in Vancouver’s Top 40 Under 40 award for young entrepreneurs, professionals, and executives.

She holds an MBA from McGill University and a BSc in Geophysical Engineering from Queen’s University.

Kathy L. Hudson

Kathy L. Hudson

Former Deputy Director for Science, Outreach & Policy, National Institutes of Health (NIH)

Dr. Kathy Hudson is the former Deputy Director for Science, Outreach, and Policy at the National Institutes of Health (NIH), where she led the science policy, legislation, communications, and outreach efforts of the NIH; and served as senior advisor to the NIH director. She directed the agency’s efforts to advance biomedical science through policy development and innovative projects and partnerships. Kathy created major new strategic and scientific initiatives including the National Center for Advancing Translational Sciences, the BRAIN initiative, the NIH Precision Medicine Initiative, and the Cancer Moonshot. She led the development of major policies that enable science to advance more rapidly including enhancing clinical trials, data sharing, and participation of patients as partners in research. She was the key NIH architect responsible for modernizing the regulations governing research with human subjects.

Kathy’s professional experience includes serving as the Acting Deputy Director of the National Center for Advancing Translational Sciences, NIH; the NIH Chief of Staff; the Assistant Director of the National Human Genome Research Institute, NIH; and the founder and Director of the Genetics and Public Policy Center at John Hopkins University. Also at Hopkins, she was an Associate Professor in the Berman Institute of Bioethics, Institute of Genetic Medicine, and Department of Pediatrics.

Kathy holds a PhD in Molecular Biology from the University of California at Berkeley, an MS in Microbiology from the University of Chicago, and a BA in Biology from Carleton College.

Gordon C. McCauley

Gordon C. McCauley

President & CEO, adMare BioInnovations

Gordon McCauley, BA, MBA, ICD.D was appointed President and CEO of adMare BioInnovations in 2016 after serving on the Board for four years. He is an accomplished life science investor and executive.

Gordon has served as President and CEO of Viable Healthworks Corp., a national healthcare service business; Allon Therapeutics Inc., a neuroscience biotechnology company that developed novel therapeutics from pre-clinical to global phase 3 studies before being sold; and as Co-Founder and Partner of NDI Capital, an institutionally backed life-science investment fund. He has also been a senior executive of several successful healthcare enterprises, and a senior advisor to several prominent Canadian political leaders.

Gordon has served as a Director of a number of private and publicly traded companies. Currently, he is a Director of adMare (and a number of its portfolio and subsidiary companies), BIOVECTRA a leading Canadian biotech and pharmaceutical CDMO, Chairs the Board of both BIOTECanada, Canada’s national biotechnology industry organization, and CGEn, Canada’s national genomics enterprise, and is a Director of Montréal InVivo. He has previously served as Chair of Life Sciences British Columbia, Acetech, The Toronto Rehab Foundation. Gordon was the first Canadian appointed to the Board of The Biotechnology Industry Organization (BIO) in Washington D.C., where he served in leadership positions until 2013.

Gordon earned a BA in Political Science from McMaster University, an MBA (with Honours) from IMD in Lausanne, Switzerland, and holds the ICD.D certification from the Institute of Corporate Directors and the Rotman School of Business at the University of Toronto.

Laurence Rulleau

Laurence Rulleau

Partner, CTI Life Sciences

Dr. Laurence Terrisse Rulleau, served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years, working at firms that include Desjardins, Yorkton, and Blackmont securities. In her experience as an analyst, she researched over 100 life sciences companies with scientific due diligence on these companies, as well as undertook market analyses and competition assessments.

Laurence was ranked the number one Canadian life sciences analyst by the Starmine survey (a Thomson Reuters Company) and number one independent analyst by Brendon Wood survey. She was involved in numerous mergers and acquisitions as well as IPOs. Laurence was also CEO of HLA-G Technologies, a biotechnology start-up based in France, and more recently, served as Vice-President Business Development of Univalor, the technology transfer office of Montreal’s university and affiliated schools. Under her responsibility at Univalor, in three years, more than 40 licences with industry were signed, and eight companies started.

Laurence has a Masters in Biology from The Université du Québec à Montréal (UQAM) and a PhD from Université de Montréal executed at Montreal Clinical Research Institute.

Michelle Savoie

Michelle Savoie

Associate Professor, Faculty of Pharmacy, Université de Montréal, and President, Consilio Manuque Inc.

Dr. Michelle Savoie has over 25 years experience in the life sciences and pharmaceutical sector. She is an Associate Professor, practical training at the Faculty of Pharmacy, Université de Montréal, and CEO, Consilio Manuque. Until July 2015, she was also CEO of Montréal InVivo.

Michelle has held strategic positions at Schering Canada, Eli Lilly Canada and Bristol-Myers Squibb, and participated on several boards including those of the Quebec Network for Personalized Healthcare (PHC), Montréal InVivo, Personalized Medicine Partnership for Cancer, International Congress on PHC, and NEOMED. She was actively involved in the creation of the Quebec Consortium for Drug Discovery, the Quebec PHC Strategy, NEOMED, and the early phase clinical research initiatives.

A biochemist by training, Michelle also completed an MBA, a Masters in Public Health, a PhD in biomedical sciences, a Masters in Law and Health Policy and the Directors Education Program of the Institute of Corporate Directors.

Meet our